SIROLIMUS DOSE-NORMALIZED TROUGHS WERE AFFECTED BY TIME POST SIROLIMUS INITIATION, CONCOMITANT TACROLIMUS THERAPY, AND MDR-1 3435C > T POLYMORPHISM IN RENAL TRANSPLANT PATIENTS WHO ARE CYP3A5 NON-EXPRESSERS
Publication
, Conference
Sam, W-J; Chamberlain, CE; Lee, S-J; Goldstein, JA; Hale, DA; Kirk, AD; Mannon, RB; Hon, YY
Published in: JOURNAL OF CLINICAL PHARMACOLOGY
September 1, 2009
Duke Scholars
Published In
JOURNAL OF CLINICAL PHARMACOLOGY
ISSN
0091-2700
Publication Date
September 1, 2009
Volume
49
Issue
9
Start / End Page
1107 / 1107
Location
San Antonio, TX
Publisher
SAGE PUBLICATIONS INC
Conference Name
38th Annual Meeting of the American-College-of-Clinical-Pharmacology
Related Subject Headings
- Pharmacology & Pharmacy
- 3214 Pharmacology and pharmaceutical sciences
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Sam, W.-J., Chamberlain, C. E., Lee, S.-J., Goldstein, J. A., Hale, D. A., Kirk, A. D., … Hon, Y. Y. (2009). SIROLIMUS DOSE-NORMALIZED TROUGHS WERE AFFECTED BY TIME POST SIROLIMUS INITIATION, CONCOMITANT TACROLIMUS THERAPY, AND MDR-1 3435C > T POLYMORPHISM IN RENAL TRANSPLANT PATIENTS WHO ARE CYP3A5 NON-EXPRESSERS. In JOURNAL OF CLINICAL PHARMACOLOGY (Vol. 49, pp. 1107–1107). San Antonio, TX: SAGE PUBLICATIONS INC.
Sam, Wai-Johnn, Christine E. Chamberlain, Su-Jun Lee, Joyee A. Goldstein, Douglas A. Hale, Allan D. Kirk, Roslyn B. Mannon, and Yuen Yi Hon. “SIROLIMUS DOSE-NORMALIZED TROUGHS WERE AFFECTED BY TIME POST SIROLIMUS INITIATION, CONCOMITANT TACROLIMUS THERAPY, AND MDR-1 3435C > T POLYMORPHISM IN RENAL TRANSPLANT PATIENTS WHO ARE CYP3A5 NON-EXPRESSERS.” In JOURNAL OF CLINICAL PHARMACOLOGY, 49:1107–1107. SAGE PUBLICATIONS INC, 2009.
Sam W-J, Chamberlain CE, Lee S-J, Goldstein JA, Hale DA, Kirk AD, et al. SIROLIMUS DOSE-NORMALIZED TROUGHS WERE AFFECTED BY TIME POST SIROLIMUS INITIATION, CONCOMITANT TACROLIMUS THERAPY, AND MDR-1 3435C > T POLYMORPHISM IN RENAL TRANSPLANT PATIENTS WHO ARE CYP3A5 NON-EXPRESSERS. In: JOURNAL OF CLINICAL PHARMACOLOGY. SAGE PUBLICATIONS INC; 2009. p. 1107–1107.
Sam, Wai-Johnn, et al. “SIROLIMUS DOSE-NORMALIZED TROUGHS WERE AFFECTED BY TIME POST SIROLIMUS INITIATION, CONCOMITANT TACROLIMUS THERAPY, AND MDR-1 3435C > T POLYMORPHISM IN RENAL TRANSPLANT PATIENTS WHO ARE CYP3A5 NON-EXPRESSERS.” JOURNAL OF CLINICAL PHARMACOLOGY, vol. 49, no. 9, SAGE PUBLICATIONS INC, 2009, pp. 1107–1107.
Sam W-J, Chamberlain CE, Lee S-J, Goldstein JA, Hale DA, Kirk AD, Mannon RB, Hon YY. SIROLIMUS DOSE-NORMALIZED TROUGHS WERE AFFECTED BY TIME POST SIROLIMUS INITIATION, CONCOMITANT TACROLIMUS THERAPY, AND MDR-1 3435C > T POLYMORPHISM IN RENAL TRANSPLANT PATIENTS WHO ARE CYP3A5 NON-EXPRESSERS. JOURNAL OF CLINICAL PHARMACOLOGY. SAGE PUBLICATIONS INC; 2009. p. 1107–1107.
Published In
JOURNAL OF CLINICAL PHARMACOLOGY
ISSN
0091-2700
Publication Date
September 1, 2009
Volume
49
Issue
9
Start / End Page
1107 / 1107
Location
San Antonio, TX
Publisher
SAGE PUBLICATIONS INC
Conference Name
38th Annual Meeting of the American-College-of-Clinical-Pharmacology
Related Subject Headings
- Pharmacology & Pharmacy
- 3214 Pharmacology and pharmaceutical sciences
- 1115 Pharmacology and Pharmaceutical Sciences